ZAGAM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zagam, and what generic alternatives are available?
Zagam is a drug marketed by Mylan and is included in one NDA.
The generic ingredient in ZAGAM is sparfloxacin. Additional details are available on the sparfloxacin profile page.
Summary for ZAGAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 93 |
| Patent Applications: | 4,782 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ZAGAM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZAGAM
US Patents and Regulatory Information for ZAGAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | ZAGAM | sparfloxacin | TABLET;ORAL | 020677-001 | Dec 19, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZAGAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan | ZAGAM | sparfloxacin | TABLET;ORAL | 020677-001 | Dec 19, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZAGAM
See the table below for patents covering ZAGAM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Czechoslovakia | 8607833 | ⤷ Try a Trial | |
| Finland | 87457 | ⤷ Try a Trial | |
| Norway | 173993 | ⤷ Try a Trial | |
| Norway | 170726 | ⤷ Try a Trial | |
| Australia | 6427786 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZAGAM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0221463 | SPC/GB95/012 | United Kingdom | ⤷ Try a Trial | SPC/GB95/012: 20061024, EXPIRES: 20090106 |
| 0375658 | C300014 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ORBIFLOXACIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; REGISTRATION NO/DATE: NL 9652 - NL 9654 20000208 |
| 0375658 | 2000C/020 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ORBIFLOXACINE; NAT. REGISTRATION NO/DATE: 282 IS 58 F3 20000228; FIRST REGISTRATION: GB VM00201/4036 19980608 |
| 0375658 | 25/2000 | Austria | ⤷ Try a Trial | PRODUCT NAME: ORBIFLOXACIN; NAT. REGISTRATION NO/DATE: 8-00439, 8-00440, 8-00438 20000225; FIRST REGISTRATION: GB VM 00201/4035 - 00201/4037 19980608 |
| 0375658 | SPC/GB98/036 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ORBIFLOXACIN; REGISTERED: UK 00201/4035 19980608; UK 00201/4036 19980608; UK 00201/4037 19980608 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
